Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03132675
Title pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment (PISCES)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors OncoSec Medical Incorporated
Indications

melanoma

Therapies

IL-12 gene + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.